160 related articles for article (PubMed ID: 34992505)
1. Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma.
Ying L; Cheng M; Lu Y; Tao Q; Chen X; Shen B; Xiong F; Hu Z; Wang D; Li X
Pathol Oncol Res; 2021; 27():1610075. PubMed ID: 34992505
[TBL] [Abstract][Full Text] [Related]
2. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
3. A Cell Cycle Progression-Derived Gene Signature to Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma.
Hui Y; Leng J; Jin D; Liu D; Wang G; Wang Q; Wang Y
Dis Markers; 2021; 2021():1986159. PubMed ID: 34721731
[TBL] [Abstract][Full Text] [Related]
4. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
5. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients.
Wang J; Han K; Zhang C; Chen X; Li Y; Zhu L; Luo T
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33988674
[TBL] [Abstract][Full Text] [Related]
7. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
8. Construction of a Novel Oxidative Stress Response-Related Gene Signature for Predicting the Prognosis and Therapeutic Responses in Hepatocellular Carcinoma.
Hong J; Cai X
Dis Markers; 2022; 2022():6201987. PubMed ID: 36133439
[TBL] [Abstract][Full Text] [Related]
9. Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma.
Huo J; Wu L; Zang Y; Dong H; Liu X; He F; Zhang X
BMC Cancer; 2021 Jan; 21(1):31. PubMed ID: 33413205
[TBL] [Abstract][Full Text] [Related]
10. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
[TBL] [Abstract][Full Text] [Related]
11. Increased E2F2 predicts poor prognosis in patients with HCC based on TCGA data.
Zeng Z; Cao Z; Tang Y
BMC Cancer; 2020 Oct; 20(1):1037. PubMed ID: 33115417
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
Jiang W; Wu T; Shi X; Xu J
Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
Li X; Lin J; Pan Y; Cui P; Xia J
Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
[No Abstract] [Full Text] [Related]
14. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
15. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis.
Xiao H; Wang B; Xiong HX; Guan JF; Wang J; Tan T; Lin K; Zou SB; Hu ZG; Wang K
J Cell Physiol; 2021 Apr; 236(4):2572-2591. PubMed ID: 32853412
[TBL] [Abstract][Full Text] [Related]
16. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
[TBL] [Abstract][Full Text] [Related]
17. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma.
Tian MX; Liu WR; Wang H; Zhou YF; Jin L; Jiang XF; Tao CY; Tang Z; Zhou PY; Fang Y; Qu WF; Ding ZB; Peng YF; Dai Z; Qiu SJ; Zhou J; Lau WY; Fan J; Shi YH
BMC Med; 2019 Jun; 17(1):106. PubMed ID: 31164128
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
19. β-Catenin Expression Correlates With Prognosis in Hepatocellular Carcinoma Patients Treated With Transcatheter Arterial Chemoembolization.
Xu X; Gao D; Yuan X; Liu LI; Zhang X; Liang X; Chen S; Ai M; Chen BO; Shi D; Yang Z; Hoffman RM; Xu J
Anticancer Res; 2019 Mar; 39(3):1129-1134. PubMed ID: 30842141
[TBL] [Abstract][Full Text] [Related]
20. Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma.
Zeng Z; Jiang X; Pan Z; Zhou R; Lin Z; Tang Y; Cui Y; Zhang E; Cao Z
Aging (Albany NY); 2021 Oct; 13(19):22802-22829. PubMed ID: 34607313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
